Recipient candidates may have reversible contraindications that halt the surgery temporarily and therefore, it warrants re-evaluation before transplant.
However, in some countries with limited institutional and financial resources, issues involving organ allocation process may lead to perplexity and uncertainty in terms of equity among recipient candidates, donor safety and transparency about prioritisation within the waiting list [ 17].
was the leading recipient among candidates, with $36,400.
Recipients of candidate vaccine were administered lyophilised RTS,S reconstituted with 0.5 mL of either AS02D or AS01E Adjuvant Systems.
Recipients of candidate vaccine were administered 50 µg of lyophilized RTS,S reconstituted with 500 µL of either AS02A or AS01B Adjuvant Systems.
A marked increase in anti-HBs GMTs was observed in recipients of candidate malaria vaccines 1 month post Dose 3 (Day 90); GMTs were similar in the RTS,S/AS01B (1435 mIU/mL [95% CI: 743 to 2771]) and RTS,S/AS02A (1714 mIU/mL [95% CI: 836 to 3515]) groups.
The analysis was restricted to recipients of candidate malaria vaccines and compared anti-CS GMTs between subjects that did, and those that did not, become infected with malaria during the 14 week follow-up period, from 14 days to 4 months post Dose 3 (infection was defined as P. falciparum asexual parasitemia >0/µL detected on a scheduled ADI visit or by passive case detection).
Prior recipients of candidate HIV DNA vaccines from VRC 004 (evaluation of a 4-plasmid DNA product) [20] and VRC 007 (evaluation of a 6-plasmid DNA product) [19] who consented to do so were assessed for eligibility to participate in a study evaluating a booster immunization with rAd5 [18].
The group's top recipient after presidential candidate Hillary Clinton ($10,711) was Rep. Louise Slaughter (D-N.Y ., co-chair of the Congressional Arts Caucus.
- Results from a randomized controlled trial including 380 vaccine recipients and 176 placebo recipients showed that the candidate vaccine induced anti-gD antibodies in all seronegative recipients and that these antibodies persisted for at least 6 months after vaccination.
Likewise, HSV-2 0ΔNLshoweded promise as a vaccine candidate because recipient mice survived lethal HSV-2 MS challenge at the same 100% frequency as HSV-2 MS latently infected mice (Fig. 6B).
